Spots Global Cancer Trial Database for arginine deiminase
Every month we try and update this database with for arginine deiminase cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy | NCT01910025 | Non-Hodgkin's L... | ADI-PEG 20 | 20 Years - | Polaris Group | |
| ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme | NCT04587830 | Glioblastoma Mu... | ADI-PEG20 Temozolomide | 20 Years - 75 Years | Polaris Group | |
| Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer | NCT01497925 | Solid Tumors Prostate Cancer | ADI-PEG 20 | 18 Years - | Polaris Group | |
| ADI-PEG in Patients With Metastatic Melanoma | NCT00029900 | Melanoma Neoplasm Metast... | ADI PEG | - | FDA Office of Orphan Products Development | |
| Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | NCT02102022 | Advanced Gastro... Hepatocellular ... Gastric Cancer Colorectal Canc... | ADI-PEG 20 plus... | 18 Years - | Polaris Group | |
| PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy | NCT01910025 | Non-Hodgkin's L... | ADI-PEG 20 | 20 Years - | Polaris Group | |
| Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | NCT02101593 | Hepatocellular ... | ADI-PEG 20 | 18 Years - | Polaris Group | |
| Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer | NCT02101580 | Advanced Pancre... | ADI-PEG 20 | 18 Years - | Polaris Group | |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | NCT05712694 | Soft Tissue Sar... | ADI PEG20 Placebo | 18 Years - 99 Years | Polaris Group | |
| ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme | NCT04587830 | Glioblastoma Mu... | ADI-PEG20 Temozolomide | 20 Years - 75 Years | Polaris Group | |
| PH 2 ADI-PEG 20 Acute Myeloid Leukemia | NCT01910012 | Acute Myeloid L... | ADI-PEG 20 | 18 Years - | Polaris Group | |
| Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | NCT02102022 | Advanced Gastro... Hepatocellular ... Gastric Cancer Colorectal Canc... | ADI-PEG 20 plus... | 18 Years - | Polaris Group | |
| Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy | NCT01287585 | Hepatocellular ... | ADI-PEG 20 (arg... Placebo Best Supportive... | 18 Years - | Polaris Group | |
| Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma | NCT01665183 | Cutaneous Melan... | ADI-PEG 20 | 18 Years - | Polaris Group | |
| Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer | NCT01497925 | Solid Tumors Prostate Cancer | ADI-PEG 20 | 18 Years - | Polaris Group | |
| Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy | NCT01287585 | Hepatocellular ... | ADI-PEG 20 (arg... Placebo Best Supportive... | 18 Years - | Polaris Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
